Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.2900
-0.0038 (-1.29%)
At close: Aug 13, 2025, 4:00 PM
0.2821
-0.0079 (-2.72%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Intensity Therapeutics Employees
As of December 31, 2024, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,796,857
Market Cap
13.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INTS News
- 2 days ago - Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - PRNewsWire
- 6 days ago - Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 10 days ago - Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 - PRNewsWire
- 6 weeks ago - Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - PRNewsWire